These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 10907613)
21. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Parellada E; Lomeña F; Catafau AM; Bernardo M; Font M; Fernández-Egea E; Pavía J; Gutierrez F Psychiatry Res; 2004 Jan; 130(1):79-84. PubMed ID: 14972370 [TBL] [Abstract][Full Text] [Related]
22. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Farde L; Nordström AL Psychopharmacol Ser; 1993; 10():94-100. PubMed ID: 8103229 [No Abstract] [Full Text] [Related]
23. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375 [TBL] [Abstract][Full Text] [Related]
24. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237 [TBL] [Abstract][Full Text] [Related]
28. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950 [TBL] [Abstract][Full Text] [Related]
29. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study. Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444 [TBL] [Abstract][Full Text] [Related]
30. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489 [TBL] [Abstract][Full Text] [Related]
31. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348 [TBL] [Abstract][Full Text] [Related]
36. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. Sabri O; Erkwoh R; Schreckenberger M; Cremerius U; Schulz G; Dickmann C; Kaiser HJ; Steinmeyer EM; Sass H; Buell U J Nucl Med; 1997 Feb; 38(2):181-8. PubMed ID: 9025731 [TBL] [Abstract][Full Text] [Related]
37. Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. Harasko-van der Meer C; Brücke T; Wenger S; Fischer P; Deecke L; Podreka I J Neural Transm Gen Sect; 1993; 94(3):217-21. PubMed ID: 7907218 [TBL] [Abstract][Full Text] [Related]
38. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Voruganti LP; Awad AG Can J Psychiatry; 2004 May; 49(5):285-9. PubMed ID: 15198463 [TBL] [Abstract][Full Text] [Related]
39. Remoxipride in the treatment of psychoses. Eriksson L Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):619-23. PubMed ID: 8078994 [TBL] [Abstract][Full Text] [Related]
40. Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels. Tang SW Can J Psychiatry; 1985 Jun; 30(4):249-50. PubMed ID: 2861888 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]